WWP-4X (Survo)

WWP-4X (Survo) - Glucagon / GLP-1 Dual Agonist Research Peptide

WWP-4X (Survo) is a once-weekly glucagon receptor and GLP-1 receptor dual agonist co-developed by Boehringer Ingelheim and Zealand Pharma. It is the main research peptide for characterizing paired glucagon + GLP-1 signaling, and is currently in Phase 3 trials (SYNCHRONIZE program) for obesity and MASH (metabolic dysfunction-associated steatohepatitis). It sits in the same “multi-receptor GLP-1” family as tirzepatide and retatrutide but pairs GLP-1 with glucagon specifically, not GIP.

Why Glucagon + GLP-1 Matters

The incretin peptides (semaglutide, tirzepatide) work primarily by amplifying insulin release and slowing gastric emptying. Glucagon receptor signaling is different - it increases hepatic energy expenditure and fat oxidation. Pairing glucagon with GLP-1 in a single molecule combines the caloric-intake side (GLP-1) with the energy-expenditure side (glucagon), which is the mechanistic rationale behind survodutide’s design.

Survodutide vs Tirzepatide vs Retatrutide

Three multi-receptor GLP-1 peptides often get compared in the same research literature, so the distinction matters.

All three are once-weekly. Survodutide is unique among them for pairing glucagon with GLP-1 as a two-receptor molecule; retatrutide adds GIP on top of the same pair.

Forschungsanwendungen

Survodutide is used in studies examining:

• Combined glucagon + GLP-1 signaling in a single molecule
• Hepatic energy expenditure and fat-oxidation endpoints
• MASH (metabolic dysfunction-associated steatohepatitis) models
• Body-composition endpoints vs. GLP-1 monotherapy
• Comparative research vs. tirzepatide and retatrutide
• Dose-response characterization through the published Phase 2 range

Technische Daten

Storage & Handling

Unopened vials are kept at 2-8°C under standard cold-chain conditions and remain stable for 12+ months. Reconstitution parameters, solvent compatibility, and post-reconstitution stability for Survodutide are documented in the published peer-reviewed literature and standard peptide-chemistry references.

Reference Literature

Published clinical and preclinical Survodutide literature is available through PubMed, Google Scholar, and other peer-reviewed databases. WWP does not provide protocol design, dosing guidance, or administration parameters. Those decisions rest with the researcher and any applicable institutional review board.

Common Questions About Survodutide Research

Is survodutide a GLP-1?

It contains GLP-1 agonism, but it is not a pure GLP-1. Survodutide is a dual agonist - it activates both the glucagon receptor and the GLP-1 receptor. That is what distinguishes it from single-mechanism GLP-1 peptides like semaglutide.

How does survodutide compare to tirzepatide?

They are both once-weekly dual agonists, but they pair GLP-1 with different second receptors. Tirzepatide pairs GLP-1 with GIP (both incretin pathways). Survodutide pairs GLP-1 with glucagon (incretin + energy expenditure). The published endpoints differ as a result.

How does survodutide compare to retatrutide?

Retatrutide is a triple agonist (GIP + GLP-1 + glucagon) and is essentially survodutide’s two receptors plus GIP on top. Head-to-head data does not yet exist in published form; both are in Phase 3.

Is survodutide FDA approved?

No. Survodutide is currently in Phase 3 trials (SYNCHRONIZE program) and is not approved by the FDA for any use. Every vial WWP ships is labeled and sold strictly for laboratory and research use only.

How is survodutide stored?

Ungeöffnete Fläschchen werden bei 2–8 °C gelagert und sind mindestens 12 Monate haltbar. Nach der Rekonstitution mit bakteriostatischem Wasser wird die Lösung bei 2–8 °C aufbewahrt und innerhalb von 28–30 Tagen verbraucht.

Reinheitsgarantie

Jede Charge weist eine Reinheit von ≥99 % auf. Senden Sie uns ein Analysezertifikat einer unabhängigen Prüfstelle, und wir stellen Ihnen unabhängig vom Ergebnis eine Gutschrift aus.